Last reviewed · How we verify
NCT05988073: iMMersioN
A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy
trial in Multifocal Motor Neuropathy in 413 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2028
Quick facts
| Lead sponsor | argenx |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 413 |
| Start date | 29 November 2023 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2028 |
| Sites | 113 locations across Italy, Japan, Poland, Denmark, Belgium, Sweden, Bulgaria, United States |
Conditions studied
- Multifocal Motor Neuropathy — all drugs for Multifocal Motor Neuropathy →
Sponsor
argenx — full company profile →
Who can join
18 and older, any sex, with Multifocal Motor Neuropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective longitudinal study will follow participants with Multifocal Motor Neuropathy over time and collect data on their clinical outcomes, quality of life, and use of health care resources. Participants will follow their regular visit schedule with their treating physician, except for an optional second visit occurring 7 to 14 days after the start of the study to collect biomarker data. No IMP will be administered.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
ePosters
· 2024
Verify or expand the search:
- PubMed search for NCT05988073
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multifocal Motor Neuropathy
Currently open trials in the same condition.
- NCT06537999 — A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy · Phase 2 · recruiting
- NCT06040567 — Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study · recruiting
Other argenx trials
Trials by the same sponsor.
- NCT07377396 — A Study to Assess the Safety of ARGX-124 in Healthy Volunteers · Phase 1 · recruiting
- NCT07287982 — A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration · Phase 2 · recruiting
- NCT07284420 — ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With · Phase 2 · recruiting
- NCT07294170 — ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Particip · recruiting
- NCT07091630 — A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05988073 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by argenx
- Last refreshed: 16 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05988073.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing